7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children
Primary Purpose
Urinary Tract Infections in Children
Status
Unknown status
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Longer therapy duration
Shorter therapy duration
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Tract Infections in Children focused on measuring urinary tract infections, pyelonephritis, cefuroxime, children
Eligibility Criteria
Inclusion Criteria (must have all):
- children aged from 3 months to 7 years
- clinical diagnosis of a febrile UTI at presentation according to urinalysis (white blood cells in the sediment >10 in the field of view);
- fever ≥38°C
- positive urine collection with sensitivity for cefuroxime
- treatment cefuroxime or cefuroxime axetil for 7 days
Exclusion Criteria (must have one):
- history of a UTI in the last 3 months
- prophylaxis for UTI
- antibiotic therapy in the last month
- known allergy to the study drugs
- immunosuppression therapy
- disease with immune deficiency
- children with other coexisting infection, e.g. meningitis, sepsis, pneumonia, otitis
- severe obstructive uropathy
Sites / Locations
- Children's Hospital for The Medical University of WarsawRecruiting
- The Holy Family Specialistic HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Antibiotic therapy for 10 days
Antibiotic therapy for 7 days
Arm Description
After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
Outcomes
Primary Outcome Measures
frequencies of recurrence of UTI
New onset of symptomatic UTI within the 3 months follow-up period. The recurrence of a UTI is diagnosed when the next infection is caused by the same microorganism during 3 months following the treatment of a UTI.
Secondary Outcome Measures
frequencies of reinfection of UTI
The reinfection of a UTI is diagnosed when the next infection is caused by a different bacteria.
antibiotic-associated diarrhoea (AAD), compliance
AAD is defined by the daily production of at least 3 loose or watery stools for at least 48 hours during antibiotic treatment and 7 days after administration of the antibiotic.
Compliance with the study protocol will be assessed by direct interview with the patient and/or caregiver and by measuring the amount of the fluid left in the bottle at the end of the intervention.
Full Information
NCT ID
NCT03221504
First Posted
July 7, 2017
Last Updated
March 19, 2018
Sponsor
Medical University of Warsaw
1. Study Identification
Unique Protocol Identification Number
NCT03221504
Brief Title
7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children
Official Title
7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
July 31, 2019 (Anticipated)
Study Completion Date
January 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators aim to assess the effectiveness of a 7-day compared with a 10-day course of antibiotic treatment for febrile urinary tract infections (UTIs) in children. It is formulated a hypothesis that a 7-day course of antibiotic therapy is equally effective as a 10-day course of therapy and would entail a lower risk of adverse events and better compliance.
Detailed Description
In previously published European and global guidelines, there has been no consensus among experts regarding the duration of therapy for a febrile UTI. Depending on the recommendation, the duration of treatment should be between 7-14 days.
221 patients aged 3 months to 7 years with febrile UTIs (defined as a combination of fever and leukocyturia in urine sediment) will be randomly assigned to receive a 7-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded placebo) or a 10-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded cefuroxime axetil).
The primary outcome measure will be frequencies of recurrence and reinfection of UTI during the 6 months after the intervention. The secondary outcome measures will be antibiotic-associated diarrhea and compliance.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections in Children
Keywords
urinary tract infections, pyelonephritis, cefuroxime, children
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
221 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Antibiotic therapy for 10 days
Arm Type
Active Comparator
Arm Description
After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
Arm Title
Antibiotic therapy for 7 days
Arm Type
Experimental
Arm Description
After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
Intervention Type
Other
Intervention Name(s)
Longer therapy duration
Intervention Description
Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
Intervention Type
Other
Intervention Name(s)
Shorter therapy duration
Intervention Description
Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
Primary Outcome Measure Information:
Title
frequencies of recurrence of UTI
Description
New onset of symptomatic UTI within the 3 months follow-up period. The recurrence of a UTI is diagnosed when the next infection is caused by the same microorganism during 3 months following the treatment of a UTI.
Time Frame
3 months after intervention
Secondary Outcome Measure Information:
Title
frequencies of reinfection of UTI
Description
The reinfection of a UTI is diagnosed when the next infection is caused by a different bacteria.
Time Frame
6 months after intervention
Title
antibiotic-associated diarrhoea (AAD), compliance
Description
AAD is defined by the daily production of at least 3 loose or watery stools for at least 48 hours during antibiotic treatment and 7 days after administration of the antibiotic.
Compliance with the study protocol will be assessed by direct interview with the patient and/or caregiver and by measuring the amount of the fluid left in the bottle at the end of the intervention.
Time Frame
7 days after intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (must have all):
children aged from 3 months to 7 years
clinical diagnosis of a febrile UTI at presentation according to urinalysis (white blood cells in the sediment >10 in the field of view);
fever ≥38°C
positive urine collection with sensitivity for cefuroxime
treatment cefuroxime or cefuroxime axetil for 7 days
Exclusion Criteria (must have one):
history of a UTI in the last 3 months
prophylaxis for UTI
antibiotic therapy in the last month
known allergy to the study drugs
immunosuppression therapy
disease with immune deficiency
children with other coexisting infection, e.g. meningitis, sepsis, pneumonia, otitis
severe obstructive uropathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Daniel, MD
Phone
+48696477117
Email
maria.daniel@wum.edu.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Malgorzata Pańczyk-Tomaszewska, Assistant Professor
Organizational Affiliation
Medical Univeristy of Warsaw
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Maria Daniel, MD
Organizational Affiliation
Medical Univeristy of Warsaw
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital for The Medical University of Warsaw
City
Warsaw
ZIP/Postal Code
02-091
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Daniel, MD
Phone
696477117
Ext
0048
Email
maria.daniel@wum.edu.pl
Facility Name
The Holy Family Specialistic Hospital
City
Warsaw
ZIP/Postal Code
02-544
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Daniel, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
26361319
Citation
Simoes e Silva AC, Oliveira EA. Update on the approach of urinary tract infection in childhood. J Pediatr (Rio J). 2015 Nov-Dec;91(6 Suppl 1):S2-10. doi: 10.1016/j.jped.2015.05.003. Epub 2015 Sep 7.
Results Reference
background
PubMed Identifier
17622599
Citation
Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007 Jul 11;298(2):179-86. doi: 10.1001/jama.298.2.179.
Results Reference
background
PubMed Identifier
19864673
Citation
Craig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, Hodson EM, Carapetis JR, Cranswick NE, Smith G, Irwig LM, Caldwell PH, Hamilton S, Roy LP; Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) Investigators. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2009 Oct 29;361(18):1748-59. doi: 10.1056/NEJMoa0902295. Erratum In: N Engl J Med. 2010 Apr 1;362(13):1250.
Results Reference
background
PubMed Identifier
21873693
Citation
Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management; Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011 Sep;128(3):595-610. doi: 10.1542/peds.2011-1330. Epub 2011 Aug 28.
Results Reference
background
PubMed Identifier
17611232
Citation
Montini G, Toffolo A, Zucchetta P, Dall'Amico R, Gobber D, Calderan A, Maschio F, Pavanello L, Molinari PP, Scorrano D, Zanchetta S, Cassar W, Brisotto P, Corsini A, Sartori S, Da Dalt L, Murer L, Zacchello G. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ. 2007 Aug 25;335(7616):386. doi: 10.1136/bmj.39244.692442.55. Epub 2007 Jul 4.
Results Reference
background
PubMed Identifier
12535494
Citation
Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev. 2003;(1):CD003966. doi: 10.1002/14651858.CD003966.
Results Reference
background
PubMed Identifier
22122295
Citation
Ammenti A, Cataldi L, Chimenz R, Fanos V, La Manna A, Marra G, Materassi M, Pecile P, Pennesi M, Pisanello L, Sica F, Toffolo A, Montini G; Italian Society of Pediatric Nephrology. Febrile urinary tract infections in young children: recommendations for the diagnosis, treatment and follow-up. Acta Paediatr. 2012 May;101(5):451-7. doi: 10.1111/j.1651-2227.2011.02549.x. Epub 2012 Jan 3.
Results Reference
background
PubMed Identifier
29500209
Citation
Daniel M, Szajewska H, Panczyk-Tomaszewska M. 7-day compared with 10-day antibiotic treatment for febrile urinary tract infections in children: protocol of a randomised controlled trial. BMJ Open. 2018 Mar 2;8(3):e019479. doi: 10.1136/bmjopen-2017-019479.
Results Reference
derived
Links:
URL
https://www.nice.org.uk/guidance/qs36
Description
National Institute for Health and Care Excellence. Urinary tract infections in children and young people 2013 July
URL
http://uroweb.org/guideline/paediatric-urology/#3
Description
European Association of Urology; European Society for Pediatric Urology Urinary tract infections in children: EAU/ESPU guidelines.
URL
http://www.cps.ca/en/documents/position/urinary-tract-infections-in-children
Description
Canadian Paediatric Society, Urinary tract infection in infants and children: Diagnosis and management
Learn more about this trial
7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children
We'll reach out to this number within 24 hrs